EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.

Abstract

Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have become key therapeutic agents for non-small cell lung cancer (NSCLC) patients with EGFR mutation, little is known about the efficacy of EGFR-TKIs according to different treatment timings.